An Open Label, Randomized, Parallel, Single Dose Study to Investigate Safety and Pharmacokinetics Following Intravenous Administration and Subcutaneous Administration of GSK1550188 in Healthy Japanese Males.

Trial Profile

An Open Label, Randomized, Parallel, Single Dose Study to Investigate Safety and Pharmacokinetics Following Intravenous Administration and Subcutaneous Administration of GSK1550188 in Healthy Japanese Males.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jun 2017

At a glance

  • Drugs Belimumab (Primary) ; Belimumab (Primary)
  • Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Lupus nephritis; Membranous glomerulonephritis; Myasthenia gravis; Myositis; Renal transplant rejection; Sjogren's syndrome; Systemic lupus erythematosus; Systemic scleroderma
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 05 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Jan 2012 New trial record
    • 26 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top